Christopher A Marlett - Net Worth and Insider Trading
Christopher A Marlett Net Worth
The estimated net worth of Christopher A Marlett is at least $2 Million dollars as of 2024-11-06. Christopher A Marlett is the Director of Cue Biopharma Inc and owns about 768,503 shares of Cue Biopharma Inc (CUE) stock worth over $1 Million. Christopher A Marlett is the 10% Owner of ClearSign Technologies Corp and owns about 363,780 shares of ClearSign Technologies Corp (CLIR) stock worth over $334,714. Christopher A Marlett is also the Director, 10% Owner of The Arena Group Holdings Inc and owns about 137,878 shares of The Arena Group Holdings Inc (AREN) stock worth over $85,484. Details can be seen in Christopher A Marlett's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher A Marlett has not made any transactions after 2019-12-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Christopher A Marlett
Christopher A Marlett Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Christopher A Marlett owns 5 companies in total, including Cue Biopharma Inc (CUE) , The Arena Group Holdings Inc (AREN) , and ClearSign Technologies Corp (CLIR) among others .
Click here to see the complete history of Christopher A Marlett’s form 4 insider trades.
Insider Ownership Summary of Christopher A Marlett
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CUE | Cue Biopharma Inc | 2019-12-31 | director |
| AREN | The Arena Group Holdings Inc | 2017-12-05 | director & 10 percent owner & Chief Executive Officer |
| CLIR | ClearSign Technologies Corp | 2012-04-24 | 10 percent owner |
 | | 2004-12-17 | director & 10 percent owner |
| | 2023-07-25 | director & 10 percent owner & CEO |
Christopher A Marlett Latest Holdings Summary
Christopher A Marlett currently owns a total of 3 stocks. Among these stocks, Christopher A Marlett owns 768,503 shares of Cue Biopharma Inc (CUE) as of December 31, 2019, with a value of $1 Million and a weighting of 75.77%. Christopher A Marlett owns 363,780 shares of ClearSign Technologies Corp (CLIR) as of April 24, 2012, with a value of $334,714 and a weighting of 19.3%. Christopher A Marlett also owns 137,878 shares of The Arena Group Holdings Inc (AREN) as of December 5, 2017, with a value of $85,484 and a weighting of 4.93%.
Latest Holdings of Christopher A Marlett
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CUE | Cue Biopharma Inc | 2019-12-31 | 768,503 | 1.71 | 1,314,140 |
| CLIR | ClearSign Technologies Corp | 2012-04-24 | 363,780 | 0.92 | 334,714 |
| AREN | The Arena Group Holdings Inc | 2017-12-05 | 137,878 | 0.62 | 85,484 |
Holding Weightings of Christopher A Marlett
Christopher A Marlett Form 4 Trading Tracker
According to the SEC Form 4 filings, Christopher A Marlett has made a total of 3 transactions in Cue Biopharma Inc (CUE) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Cue Biopharma Inc is the sale of 24,700 shares on December 31, 2019, which brought Christopher A Marlett around $402,116.
According to the SEC Form 4 filings, Christopher A Marlett has made a total of 0 transactions in ClearSign Technologies Corp (CLIR) over the past 5 years. The most-recent trade in ClearSign Technologies Corp is the sale of 0 shares on April 24, 2012, which brought Christopher A Marlett around $0.
According to the SEC Form 4 filings, Christopher A Marlett has made a total of 0 transactions in The Arena Group Holdings Inc (AREN) over the past 5 years. The most-recent trade in The Arena Group Holdings Inc is the acquisition of 1,401 shares on December 5, 2017, which cost Christopher A Marlett around $43,779.
Insider Trading History of Christopher A Marlett
- 1
Christopher A Marlett Trading Performance
GuruFocus tracks the stock performance after each of Christopher A Marlett's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Christopher A Marlett is 57.19%. GuruFocus also compares Christopher A Marlett's trading performance to market benchmark return within the same time period. The performance of stocks bought by Christopher A Marlett within 3 months outperforms 10 times out of 11 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Christopher A Marlett's insider trading performs compared to the benchmark.
Performance of Christopher A Marlett
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.72 | | | | | |
| Relative Return to S&P 500(%) | 16.62 | | | | | |
Christopher A Marlett Ownership Network
Ownership Network List of Christopher A Marlett
Ownership Network Relation of Christopher A Marlett
Christopher A Marlett Owned Company Details
What does Cue Biopharma Inc do?
Who are the key executives at Cue Biopharma Inc?
Christopher A Marlett is the director of Cue Biopharma Inc. Other key executives at Cue Biopharma Inc include President and CSO Anish Suri , director & CEO Daniel R Passeri , and Chief Medical Officer Matteo Levisetti .
Cue Biopharma Inc (CUE) Insider Trades Summary
Over the past 18 months, Christopher A Marlett made no insider transaction in Cue Biopharma Inc (CUE). Other recent insider transactions involving Cue Biopharma Inc (CUE) include a net purchase of 4,000 shares made by Anish Suri , and a net purchase of 3,000 shares made by Daniel R Passeri .
In summary, during the past 3 months, insiders sold 0 shares of Cue Biopharma Inc (CUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cue Biopharma Inc (CUE) were sold and 7,000 shares were bought by its insiders, resulting in a net purchase of 7,000 shares.
Cue Biopharma Inc (CUE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cue Biopharma Inc Insider Transactions
Christopher A Marlett Mailing Address
Above is the net worth, insider trading, and ownership report for Christopher A Marlett. You might contact Christopher A Marlett via mailing address: 100 Wilshire Blvd, Santa Monica Ca 90401.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
